The cancer drug conjugate developer floated in the middle of its range, in an offering that provided exits to Takeda subsidiary Millennium Pharmaceuticals and Pfizer.
Mersana Therapeutics, a US-based antibody drug conjugate (ADC) developer backed by pharmaceutical companies Takeda and Pfizer, raised $75m in an initial public offering yesterday.
The company issued 5 million shares on the Nasdaq Global Select Market priced at $15.00 each, in the middle of the $14 to $16 range it set earlier this month.
Mersana is developing cancer treatments using an ADC platform that will allow for much higher payloads of drugs to be delivered to a patient by simultaneously…
